CJC-1295 (No DAC) acts on the GHRH receptor
Many of these symptoms can also be attributed to other factors, such as diet, lifestyle, and obesity, which are common in the patient population using semaglutide
Previous GLP-1 users were far more divided, with 52.34% trusting injections more and 43.75% trusting tablets more, suggesting confidence in tablets may grow once people move away from injectable treatment
.
The semaglutide variant for weight management, Wegovy, raked in $3.32 billion, while sales of the oral type 2 diabetes version of the drug, Rybelsus, hit $2.72 billion
Despite their therapeutic benefits, GLP-1 RAs are associated with a spectrum of adverse events, with gastrointestinal disturbances being among the most commonly reported